Vanda Pharmaceuticals (VNDA) Projected to Release Quarterly Earnings on Wednesday

Key Points

• Vanda Pharmaceuticals is expected to report Q3 2026 results before market open on October 28. Analysts forecast a loss of $0.72 per share and revenue of $69.20 million.
• The company’s previous quarter significantly missed expectations, reporting a $1.04 per-share loss versus the estimated $0.58 loss and revenue of $50.53 million versus the $61.92 million consensus.
• VNDA shares opened at $4.05, near their one-year low of $3.96. Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $13.08.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect Vanda Pharmaceuticals to announce earnings of ($0.72) per share and revenue of $69.20 million for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.46). The company had revenue of $50.53 million during the quarter, compared to the consensus estimate of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. On average, analysts expect Vanda Pharmaceuticals to post ($3.02) EPS for the current fiscal year and ($0.96) EPS for the next fiscal year.

Vanda Pharmaceuticals Price Performance

Shares of Vanda Pharmaceuticals stock opened at $4.05 on Friday. The stock has a market cap of $244.86 million, a price-to-earnings ratio of -0.87 and a beta of 0.69. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.60 and a current ratio of 1.61. The stock has a 50 day moving average price of $4.96 and a 200-day moving average price of $5.73. Vanda Pharmaceuticals has a one year low of $3.96 and a one year high of $9.94.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Monday, October 5th. Zacks Research cut shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 6th. Oppenheimer began coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, September 23rd. They set an "outperform" rating and a $10.00 price objective on the stock. B. Riley Financial reissued a "buy" rating and issued a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $13.08.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company was founded in 2003 and is headquartered in Washington, DC Its work centers on conditions involving sleep, circadian rhythms, and psychiatric health.

Vanda's commercial products include Hetlioz (tasimelteon), a melatonin receptor agonist approved in the United States for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, and Fanapt (iloperidone), an atypical antipsychotic used to treat schizophrenia in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.